Cargando…
PARP1 Deficiency Reduces Tumour Growth by Decreasing E2F1 Hyperactivation: A Novel Mechanism in the Treatment of Cancer
SIMPLE SUMMARY: PARP1 is one of the best characterized enzymes in DNA repair and an attractive target for drug design in cancer therapies. Beyond repair, PARP1 modulates the activity of several transcription factors, of which E2F1 stands out given its critical role in cell cycle regulation. Here, we...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599842/ https://www.ncbi.nlm.nih.gov/pubmed/33050515 http://dx.doi.org/10.3390/cancers12102907 |